Tyra Biosciences Inc (TYRA) FinancialsTYRATyra Biosciences Inc

Evaluating the bottom line, Tyra Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.31%, provide a clear picture of how effectively TYRA converts its operational activities into shareholder value.

In the context of the broader market, TYRA competes directly with industry leaders such as KARD and ANAB. With a market capitalization of $1.60B, it holds a leading position in the sector. When comparing efficiency, TYRA's gross margin of N/A stands against KARD's N/A and ANAB's 100.00%. Such benchmarking helps identify whether Tyra Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Tyra has reported negative earnings per share (EPS) of -0.69 for Q2 2026, missing expectations by $0.04. The company has also shown a declining net income trend, with losses projected to increase to -$45.56 million in Q2 2026.